ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

Luo, Mayao; Zhang, Yifan; Xu, Zhuofan; Wu, Chenwei; Ye, Yuedian; Liu, Rui*; Lv, Shidong*; Wei, Qiang*南方医科大学
Cell Death Discovery2022-11-29DOI: 10.1038/s41420-022-01257-1
1被引9阅读
引用收藏
分享

摘要

The androgen receptor (AR) plays an essential role in prostate cancer progression and is a key target for prostate cancer treatment. However, patients with prostate cancer undergoing androgen deprivation therapy eventually experience biochemical relapse, with hormone-sensitive prostate cancer progressing into castration-resistant prostate cancer (CRPC). The widespread application of secondary antiandrogens, such as enzalutamide, indicates that targeting AR remains the most efficient method for CRPC treatment. Unfortunately, neither can block AR signaling thoroughly, leading to AR reactivation within several months. Here, we report an approach for suppressing reactivated AR signaling in the CRPC stage. A combination of the protein phosphatase 1 subunit alpha (PP1 alpha)-specific inhibitor tautomycin and enzalutamide synergistically inhibited cell proliferation and AR signaling in LNCaP and C4-2 cells, as well as in AR variant-positive 22RV1 cells. Our results revealed that enzalutamide competed with residual androgens in CRPC, enhancing tautomycin-mediated AR degradation. In addition, the remaining competitive inhibitory role of enzalutamide on AR facilitated tautomycin-induced AR degradation in 22RV1 cells, further decreasing ARv7 levels via a full-length AR/ARv7 interaction. Taken together, our findings suggest that the combination of tautomycin and enzalutamide could achieve a more comprehensive inhibition of AR signaling in CRPC. AR degraders combined with AR antagonists may represent a new therapeutic strategy for CRPC.

学科与关键词

关键词
ANDROGEN-RECEPTORDRUG-COMBINATIONTHERAPYUBIQUITYLATIONDEPRIVATIONDEGRADATIONMECHANISMSINHIBITORSMUTATIONMDV3100
相关
加载中…
  • IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Zhang, Yifan; Liao, Yuanpeng; Luo, Mayao; Ye, Yuedian; Xu, Zhuofan; Hou, Wenli; Liu, Ruiyu; Zhai, Qiliang; Lv, Shidong*; Wei, Qiang*PROSTATE, 2023, 83(15): 1446-1457.
  • Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
    Cong, Xiaonan; He, Yundong; Wu, Haigang; Wang, Dingxiang; Liu, Yongrui; Shao, Ting; Liu, Mingyao; Yi, Zhengfang; Zheng, Jianghua; Peng, Shihong*; Ding, Tao*Frontiers in Oncology, 2021, 11: 650919.被引 4
  • Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer
    Lv, Shidong; Song, Qiong; Chen, Guang; Cheng, Erdong; Chen, Wei; Cole, Ryan; Wu, Zeyu; Pascal, Laura E.; Wang, Ke; Wipf, Peter; Nelson, Joel B.; Wei, Qiang; Huang, Wenhua*; Wang, Zhou*Journal of Clinical Investigation, 2021, 131(4): e141335.被引 34
查看全部 →

发表信息

论文状态
公开发表
期刊
Cell Death Discovery
发表日期
2022-11-29
卷期
第 8 卷, 第 1 期
页码
471
DOI
10.1038/s41420-022-01257-1
期刊等级
2区
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2020M682800]; Natural Science Foundation of Guangdong Province [2021A1515011023]; National Natural Science Foundation of China [82103276, 81872092]; Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University [2021J005]

作者

  • L

    Luo, Mayao (第一作者)

    southern med univ

  • Z

    Zhang, Yifan

    southern med univ

查看全部 8 位作者收起作者
  • X

    Xu, Zhuofan

    southern med univ

  • W

    Wu, Chenwei

    southern med univ

  • Y

    Ye, Yuedian

    southern med univ

  • L

    Liu, Rui (通讯)

    southern med univ

  • L

    Lv, Shidong (通讯)

    southern med univ

  • W

    Wei, Qiang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417